Welcome to our dedicated page for Nls Pharmaceutics SEC filings (Ticker: NLSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with orexin receptor science and merger footnotes can feel like decoding a lab notebook. NLS Pharmaceutics’ disclosures are filled with trial data tables, R&D amortization schedules, and complex equity financings that easily top 200 pages. If you have ever wondered, “How do I track NLS Pharmaceutics insider trading Form 4 transactions before a trial readout?” or “Where is the dosing cohort detail in the latest 10-Q?”—you are not alone.
Stock Titan solves the problem. Our platform ingests every NLS Pharmaceutics quarterly earnings report 10-Q filing, annual report 10-K simplified, and 8-K material events explained the moment they hit EDGAR. AI-powered summaries translate orexin-1/2 receptor jargon into plain language, flagging pivotal endpoints, cash runway, and dilution clauses. You will also see NLS Pharmaceutics Form 4 insider transactions real-time so you can monitor executive stock moves that often precede material announcements.
Want deeper context? Compare R&D spend trends using our visual tools, receive alerts on new NLS Pharmaceutics proxy statement executive compensation disclosures, and dig into NLS Pharmaceutics earnings report filing analysis without scrolling through endless exhibits. From understanding NLS Pharmaceutics SEC documents with AI to spotting NLS Pharmaceutics executive stock transactions Form 4, Stock Titan equips you for informed decisions in minutes, not hours.
NLS Pharmaceutics (NLSP) reported shareholder approval of key steps to complete its merger with Kadimastem, including a 1-for-10 reverse share split and a name change to NewcelX Ltd. The reverse split becomes effective in Switzerland on October 30, 2025 and will be reflected on Nasdaq at market open.
Following the reverse split and the merger becoming effective, the company states it will have 4,558,378 common shares issued and outstanding, plus 1,060,574 common shares issuable upon exercise of pre-funded warrants issued as merger consideration, 13,778 preferred shares, and 58,320 preferred participation certificates.
The company will file Amended and Restated Articles of Association reflecting a registered share capital of
NLS Pharmaceutics (NLSP) furnished a 6-K noting a press release announcing completion of material conditions precedent for its merger and a delisting date for Kadimastem’s shares.
Issued on October 28, 2025, the notice indicates merger milestones have been satisfied and that Kadimastem’s shares have a delisting date announced. Full details are contained in Exhibit 99.1, titled “NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem’s Shares.”
NLS Pharmaceutics Ltd. furnished a Form 6-K announcing it issued a press release titled “NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies.”
The press release, dated October 27, 2025, is included as Exhibit 99.1. The filing lists the company’s principal executive office at The Circle 6, 8058 Zurich, Switzerland and cites Commission File Number 001-39957.
NLS Pharmaceutics Ltd. filed a Post-Effective Amendment to its Form F-1 to update its resale registration for up to 5,000,000 common shares by Alpha Capital Anstalt under a committed equity facility. The company states that no additional securities are being registered and prior fees were paid.
This is a resale by the selling shareholder; NLS will not receive proceeds from those resales. Separately, NLS may sell common shares to Alpha under the March 31, 2025 Purchase Agreement for
As context, common shares outstanding were 5,206,629 as of October 22, 2025, and the Nasdaq last reported price was
NLS Pharmaceutics Ltd. (NLSP) furnished a Form 6-K announcing it issued a press release titled “NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025.” The press release is included as Exhibit 99.1.
This update indicates Nasdaq approval has been received and the parties expect to close the merger on October 30, 2025.
NLS Pharmaceutics Ltd. filed Post-Effective Amendment No. 1 to its Form F-4, maintaining registration of 70,000,000 common shares and up to 70,000,000 pre-funded warrants tied to its merger with Kadimastem. The amendment adds a prospectus supplement with updated financial statements and pro forma information.
Shareholders approved the merger on September 29, 2025. Under the final exchange ratio, Kadimastem shareholders will own approximately 84.4% of the combined company and NLS shareholders about 15.6%, with closing expected in October 2025, subject to final Nasdaq approval and customary conditions. NLS shares trade on Nasdaq as “NLSP”; the last reported price was $1.63 on October 16, 2025.
NLS reported cash and cash equivalents of $3.1 million as of June 30, 2025, an accumulated deficit of $74.8 million, and a net loss of $2,220,671 for the six months ended June 30, 2025, with financial statements prepared on a going-concern basis reflecting substantial doubt about continuing operations without additional financing.
FAQ
What is the current stock price of Nls Pharmaceutics (NLSP)?
What is the market cap of Nls Pharmaceutics (NLSP)?
